SmartBrief > Education > CEC SmartBrief > Related Stories

FDA review: Long-acting asthma drugs pose serious risks

The FDA should revoke clearance for asthma drugs known as long-acting beta agonists for children in light of clinical evidence linking them to a higher risk of asthma attacks and death, according to a review from the agency's drug-safety personnel. The FDA plans to gather a panel of outside experts this week to evaluate the safety of AstraZeneca's Symbicort, Novartis AG's Foradil and GlaxoSmithKline's Advair and Serevent.

Reuters | 12/05 Bookmark and Share

This story published in CEC SmartBrief on 12/09/2008





Get stories like these delivered daily for FREE:
CEC SmartBrief
Designed specifically for special education professionals, CEC SmartBrief is a FREE daily e-mail newsletter. It provides the latest education news and information you need to stay on top of issues that are important to you. Learn more